IsoRay Medical™, Inc. Announces Appointment of Dr. Steven M. Kurtzman as Medical Advisor

RICHLAND, Wash.--(BUSINESS WIRE)--Feb. 1, 2006--IsoRay Medical™, Inc. (OTCBB:ISRY) of Richland, WA, the world's only manufacturer and distributor of the Cesium-131 radioisotope used in the treatment of prostate cancer and other malignant diseases, has announced the appointment of Dr. Steven M. Kurtzman as Medical Advisor.

Dr. Kurtzman has extensive experience in the treatment of prostate cancer and is one of the most experienced physicians in the world using the latest technology advancement in prostate seed brachytherapy, the Cesium-131 radioisotope. He is certified by the American Board of Radiology-Radiation Oncology and currently serves as Director of Brachytherapy for Western Radiation Oncology in San Mateo, California.

"Dr. Kurtzman is one of the medical community's leading innovators and early adopters of new technology for the treatment of prostate cancer using seed brachytherapy. We are very pleased to have his clinical expertise and we welcome and value his advice and counsel," said Roger Girard, chairman and CEO of IsoRay Medical™ Inc.

"My clinical experience with Cesium-131 has convinced me this radioisotope offers significant benefits for prostate cancer patients over Iodine and Palladium," said Dr Kurtzman. "I believe it will fast become the isotope of choice for seed brachytherapy because the high energy and short half-life. The easily achieved homogeneous dose distribution coupled with the quick resolution of the side effects normally associated with brachytherapy makes Cesium-131 a very attractive option for patients choosing seed brachytherapy for their prostate cancer treatment."

Dr. Kurtzman is a graduate of Case Western Reserve University School of Medicine and completed his internship in Internal Medicine at Pennsylvania Hospital in Philadelphia. He completed his Residency in Radiation Oncology at the Hospital of the University of Pennsylvania.

IsoRay Medical™ Inc. is the world's only manufacturer and distributor of Cesium-131, the latest technology advancement in the seed brachytherapy treatment of prostate cancer. Prostate cancer patients can now receive Cesium-131 seed brachytherapy at over 36 cancer therapy sites across the United States. The Company recently announced the opening of a new manufacturing facility located in Richland, Washington.

About IsoRay

IsoRay, Inc., through its subsidiary, IsoRay Medical™, Inc., is the sole producer of the Cesium-131 brachytherapy seed, used to treat prostate and other cancers. The Cesium-131 seed offers a significantly shorter half-life than the two other isotopes commonly used for brachytherapy, which results in a substantially faster delivery of therapeutic radiation, lower probability of cancer cell survival and reduction of the longevity of common brachytherapy side effects. IsoRay is based in Richland, Washington. More information is available about IsoRay at www.isoray.com.

Safe Harbor Statement

Statements in this news release about IsoRay's future expectations, including: the advantages of our Cesium131 seed, the level of market share our seed may attain, and all other statements in this release, other than historical facts, are forward-looking statements. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, and our ability to enforce our intellectual property rights, and other risks detailed from time to time in IsoRay's reports filed with the SEC.

Contacts

IsoRay, Inc., Richland
Roger Girard, 206-849-6507
rgirard@isoray.com

-or-

The Bartlett Group Public Relations
Barry Bartlett, 206-285-0673
Cell: 206-335-4694
barry@bartlettgrouppr.com